Abstract

Amyloid formation in the pancreatic islets due to aggregation of human islet amyloid polypeptide (hIAPP) contributes to reduced β-cell mass and function in type 2 diabetes (T2D) and islet transplantation. Protein kinase B (PKB) signaling plays a key role in the regulation of β-cell survival, function and proliferation. In this study, we used human and hIAPP-expressing transgenic mouse islets in culture as two ex vivo models of human islet amyloid formation to: 1. Investigate the effects of amyloid formation on PKB phosphorylation in primary islet β-cells; 2. Test if inhibition of amyloid formation and/or interleukin-1β (IL-1β) signaling in islets can restore the changes in β-cell phospho-PKB levels mediated by amyloid formation. Human and hIAPP-expressing mouse islets were cultured in elevated glucose with an amyloid inhibitor (Congo red) or embedded within collagen matrix to prevent amyloid formation. To block the IL-1β signaling, human islets were treated with an IL-1 receptor antagonist (anakinra) or a glucagon-like peptide-1 agonist (exenatide). β-cell phospho-PKB levels, proliferation, apoptosis, islet IL-1β levels and amyloid formation were assessed. Amyloid formation in both cultured human and hIAPP-expressing mouse islets reduced β-cell phospho-PKB levels and increased islet IL-1β levels, both of which were restored by prevention of amyloid formation either by the amyloid inhibitor or embedding islets in collagen matrix, resulting in improved β-cell survival. Furthermore, inhibition of IL-1β signaling by treatment with anakinra or exenatide increased β-cell phospho-PKB levels, enhanced proliferation and reduced apoptosis in amyloid forming human islets during 7-day culture. These data suggest that amyloid formation leads to reduced PKB phosphorylation in β-cells which is associated with elevated islet IL-1β levels. Inhibitors of amyloid or amyloid-induced IL-1β production may provide a new approach to restore phospho-PKB levels thereby enhance β-cell survival and proliferation in conditions associated with islet amyloid formation such as T2D and clinical islet transplantation.

Highlights

  • Islet amyloid polypeptide (IAPP; amylin) [1, 2] is a 37-amino acid peptide hormone that is normally produced and secreted along with insulin from islet β-cells [3]

  • Biosynthetic human IAPP (hIAPP) aggregates reduce β-cell phospho-Protein kinase B (PKB) levels and proliferation rate in human and hIAPP-expressing transgenic mouse islets, both of which are prevented by the amyloid inhibitor Congo red

  • The reduction in β-cell phospho-PKB levels in hIAPP+/transgenic mouse islets and human islets during amyloid formation correlated with the reduced rate of proliferation (Figs 1E and 2F) and increased rate of apoptosis (Figs 1F and 2G)

Read more

Summary

Introduction

Islet amyloid polypeptide (IAPP; amylin) [1, 2] is a 37-amino acid peptide hormone that is normally produced and secreted along with insulin from islet β-cells [3]. Human IAPP (hIAPP) aggregates are toxic to β-cells [5,6,7,8] and contribute to progressive βcell dysfunction and death in type 2 diabetes (T2D) [4, 9,10,11] as well as in cultured [6,7,8] and transplanted islets [12,13,14,15]. While mechanisms that mediate β-cell toxic effects of hIAPP aggregates have been extensively studied, our current knowledge about the effects of hIAPP aggregates on β-cell proliferation is very limited

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call